Insight Molecular Diagnostics publishes Q3 2026 earnings call transcript
IMDX•Insight Molecular Diagnostics expects to complete additional GraftAssureDx studies by year-end and submit its FDA response before the Jan. 21, 2027, deadline. Management said about 75 FDA review days remain and planned launch immediately following authorization.
1. FDA response timeline
Insight Molecular Diagnostics held its third-quarter 2026 earnings call on Nov. 16. Management expects to complete additional GraftAssureDx studies by year-end and submit its response to the FDA before the Jan. 21, 2027, deadline. About 75 FDA review days remain, and the company plans to launch immediately following authorization, though the agency could extend its review.
2. Registry and expenses
Enrollment has begun in the GALACTIC registry, but management expects limited near-term revenue from the registry and beta-site programs. Research and development expenses fell to $3.8 million from a peak of $5.8 million in the fourth quarter of 2025 as spending on the FDA program declined.




